Treatment of Acute Toxoplasmosis in the Congenitally Infected Newborn or Infant
Congenital toxoplasmosis presents a distinct clinical challenge in the neonatal and early infant period. Congenitally infected newborns and infants require a dedicated, prolonged treatment approach that differs from management in older children or immunocompromised adults.
Clinical Scenario
This protocol applies to congenitally infected newborns and infants diagnosed with congenital toxoplasmosis. The presentation may range from asymptomatic infection detected at birth to symptomatic disease, and the treatment course is adjusted accordingly.
Treatment Approach
Congenitally infected newborns are generally treated with a combination of an antiparasitic agent, a sulfonamide, and a folate supplement. Treatment is continued over an extended course of 12 months, with dosing stages that vary based on the infant's age and symptom status.
Specific dosing stages, adjustments, and the complete regimen are available in the full protocol.
References
- Congenitally infected newborns are generally treated with pyrimethamine, a sulfonamide, and leucovorin for 12 months.
View source ↗